Archive

Archive

This is the collection of Archive posts.

Hematologic Malignancies

Vanda-VTR-297-1101-A Phase I multicenter, open label, dose-escalation study to determine the maximum tolerated does for Trichostatin A in subjects with replapsed or refractory Hematologic Malignancies. Read More

Epithelial Tumors

PSI Oxus- ColoAD 1003-Phase 1 multicentre, open label study of enadenotucirev combined with PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors. Read More

Myelofibrosis

Constellation-0610-02- A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion… Read More

Solid Tumors

I-MAB Biopharma, Co., LTD-TJ011133ED1101 which is a Phase 1 Study of TJ011133 Administered alone or in combination with Pembrolizumab or Rituximab in subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma… Read More

Lymphoma

LAM Therapeutics-LAM-002A-NHL-CLN01-A Phase 1 dose escalation study of the safety and pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) administered orally in subjects with relapsed or refractory B-Cell Non-Hodgkin’s Lymphoma I-MAB Biopharma,… Read More

Lung Cancer

Heat-HA110-102- A Phase 1B/2 Study of Viagenpumatucel-L (HS-110) in Combination with Multiple Treatment Regimens in Patients with Non-Small Cell Lung Cancer (The “Durga” Trial)… Read More